Chromophobe Renal Cell Carcinoma (ChRCC): Comprehensive Research Report

1. Disease Information

Overview

Chromophobe renal cell carcinoma (ChRCC) is a distinct malignant epithelial neoplasm of the kidney, believed to arise from the intercalated cells of the distal nephron/collecting duct (in contrast to clear cell RCC, which arises from proximal tubule cells) (PMID:25155756). It is the third most common renal cell carcinoma subtype after clear cell RCC (ccRCC) and papillary RCC, accounting for approximately 5–7% (range 5–10%) of all RCC cases. It is characterized histologically by large polygonal cells with prominent cell membranes, finely reticulated ("wispy") pale cytoplasm, perinuclear halos, and raisinoid (wrinkled) nuclei, and molecularly by a distinctive pattern of multiple whole-chromosome losses and a comparatively low point-mutation burden. ChRCC is generally regarded as a tumor of relatively low malignant potential with favorable prognosis compared with clear cell and most papillary RCCs, though a subset — particularly tumors with sarcomatoid dedifferentiation — behaves aggressively.

Key Identifiers

MONDO ID: MONDO:0017885
Orphanet ID: ORPHA:319303
ICD-11: XH6153 (Renal cell carcinoma, chromophobe type); parent code 2C90 (Malignant neoplasms of kidney, except renal pelvis)
ICD-O-3 morphology code: 8270/3
OMIM: No disease-specific OMIM entry exists for sporadic ChRCC; it falls under the general nonpapillary renal cell carcinoma entry OMIM #144700. Birt–Hogg–Dubé syndrome (the principal hereditary predisposition syndrome) is OMIM #135150 (FLCN gene, OMIM 607273).
MeSH: Carcinoma, Renal Cell (D002292); no distinct MeSH heading for the chromophobe subtype specifically, indexed under this parent term.

Synonyms

Chromophobe adenocarcinoma of kidney; chromophobe carcinoma of kidney; chromophobe cell carcinoma of kidney; chromophobe cell renal carcinoma; chromophobe renal cell adenocarcinoma; ChRCC (common abbreviation).

Data Source Character

Information on ChRCC is derived predominantly from aggregated disease-level resources: multi-institutional surgical pathology case series (e.g., 145-case and 53-case cohorts), national cancer registries (SEER), and large consortium genomic studies (The Cancer Genome Atlas [TCGA] KICH cohort, n=66) (PMID:25155756; PMID:18813125). Individual-patient-level EHR data are less commonly published given the tumor's rarity; most clinical outcome data come from retrospective institutional or registry-based cohorts rather than prospective clinical trials specific to this histology, reflecting the broader challenge of studying rare RCC subtypes.

2. Etiology

Disease Causal Factors

The great majority (~95%+) of ChRCC cases are sporadic, arising from somatic (acquired) genomic events — principally large-scale chromosomal losses and, in a subset, TP53/PTEN pathway mutations and mitochondrial DNA (mtDNA) alterations (PMID:25155756). A minority of cases occur in the context of hereditary tumor-predisposition syndromes, most notably Birt–Hogg–Dubé (BHD) syndrome, in which ChRCC (and the closely related hybrid oncocytic/chromophobe tumor, HOCT) is the dominant renal tumor histology.

Genetic Risk Factors

Birt–Hogg–Dubé syndrome (FLCN, OMIM 607273, chr17p11.2). Autosomal dominant loss-of-function mutations in the folliculin (FLCN) tumor suppressor gene cause BHD syndrome, characterized by fibrofolliculomas, pulmonary cysts/spontaneous pneumothorax, and multiple, often bilateral, renal tumors — most commonly hybrid oncocytic/chromophobe tumors and chromophobe RCC, followed by clear cell and papillary histologies (PMID:36258004). Comparative genomic studies show BHD-associated ChRCC/HOCT is molecularly distinct from sporadic ChRCC, lacking the characteristic sporadic-ChRCC chromosome-loss signature and instead showing FLCN biallelic inactivation with mTORC1 pathway hyperactivation (PMC10200853).

Cowden syndrome / PTEN hamartoma tumor syndrome (PTEN, OMIM 601728). Germline PTEN mutations confer elevated lifetime risk of renal cell carcinoma (in addition to breast, thyroid, and endometrial cancer), with RCC risk estimated in some cohorts to approach 15–34% lifetime; ChRCC is one of the reported histologies. Somatically, PTEN is also the second most frequently mutated gene in sporadic ChRCC (~9% of TCGA cases) (PMID:25155756), converging genetic evidence on PTEN/mTOR pathway dysregulation as a recurring driver axis.

Tuberous sclerosis complex (TSC1/TSC2, OMIM #191100/#613254) and germline succinate dehydrogenase (SDH) mutations are associated with distinct renal tumor entities (angiomyolipoma/eosinophilic solid-and-cystic RCC for TSC; SDH-deficient RCC for SDHB/SDHC/SDHD) that enter the differential diagnosis of, and occasionally overlap morphologically with, chromophobe/oncocytic tumors, though these are separate WHO entities rather than ChRCC itself.

Somatic driver landscape (TCGA, n=66 tumors) (PMID:25155756): - TP53 — most frequently mutated gene, ~32% of cases; mutations correlate with decreased expression of p53 transcriptional targets and are enriched in the more aggressive "eosinophilic"/high-grade subset. - PTEN — ~9% of cases (nonsilent mutations). - mTOR pathway — mutations in MTOR, NRAS, TSC1, and TSC2 collectively occur in ~23% of cases, converging on mTORC1 hyperactivation as a major pathway. - TERT promoter structural rearrangements — recurrent structural breakpoints juxtapose the TERT promoter with strong enhancers, correlating with markedly elevated TERT expression and localized hypermutation ("kataegis") — a mechanism of telomerase reactivation distinct from the point mutations/amplifications seen in other cancers. - ~40% of tumors have no identified driver mutation in a known oncogene/tumor suppressor, implicating the characteristic chromosomal-loss pattern itself (see Genetic/Molecular section) as a primary oncogenic event.

Environmental Risk Factors

No environmental exposure has been specifically and robustly linked to ChRCC as distinct from RCC broadly. General RCC risk factors — cigarette smoking, obesity, hypertension, acquired cystic kidney disease in dialysis patients, and occupational exposure to trichloroethylene — apply to renal cancer as a class; ChRCC-specific epidemiologic data isolating these exposures are limited given the tumor's rarity.

Protective Factors

No specific genetic or environmental protective factors have been established for ChRCC; general RCC-protective associations (e.g., physical activity, moderate alcohol intake) reported in broader RCC epidemiology have not been separately validated for the chromophobe subtype.

Gene-Environment Interactions

Not well characterized for ChRCC specifically; the tumor's genomic architecture (whole-chromosome loss plus a low point-mutation burden) suggests a less environmentally mutagen-driven pathogenesis than smoking-associated urothelial or some clear-cell RCC cases, consistent with its occurrence at a somewhat younger mean age and with strong intrinsic genomic instability as the dominant driver mechanism.

3. Phenotypes

Because ChRCC is a solid tumor, its "phenotypes" are principally clinical presenting features, laboratory/imaging findings, and pathologic characteristics rather than a syndromic multi-organ phenotype (except in the context of BHD syndrome, discussed above).

Clinical Signs and Symptoms

Often asymptomatic, incidentally discovered on imaging performed for unrelated indications — an increasingly common presentation pattern for renal masses generally.
Flank pain — HPO: HP:0030057 (Flank pain)
Hematuria — HPO: HP:0000790 (Hematuria)
Palpable abdominal/flank mass — HPO: HP:0031817 (Abdominal mass) / HP:0031279 (Renal mass, if available) — a palpable renal mass, when present with pain and hematuria, forms the classic (but now uncommon) triad seen more with advanced-stage disease.
Weight loss — HPO: HP:0001824
Fatigue — HPO: HP:0012378

Phenotype Characteristics

Age of onset: Adult-onset; mean age at diagnosis ~59 years (range 27–82 in the largest surgical series) (PMID:18813125); somewhat younger on average than clear cell RCC.
Severity/progression: Most tumors behave indolently (low-grade, low metastatic potential); a minority show aggressive behavior, particularly with sarcomatoid or rhabdoid dedifferentiation, high nuclear grade, or the eosinophilic morphologic variant, which — despite resembling benign oncocytoma — can behave more aggressively than classic ChRCC.
Multifocality/bilaterality: Present in ~8% and ~3% of cases respectively in sporadic disease (PMID:18813125); bilaterality and multifocality are much more common in BHD-associated disease and should prompt genetic evaluation.
Tumor size at diagnosis: Frequently large; mean ~8.0 cm (range 1.0–30.0 cm) in surgical series, often larger than clear cell RCC at diagnosis despite favorable behavior (PMID:18813125).

Imaging Findings (a major "phenotype" category for renal masses)

Homogeneous, well-circumscribed solid renal mass, often hypovascular relative to clear cell RCC.
Central stellate scar with "spoke-wheel"-pattern enhancement on contrast CT/MRI — reported in a substantial minority of cases (historically ~27% in early case series) and classically associated with (but not specific for, and overlapping with) oncocytoma (PMID:15479284).
Segmental enhancement inversion on multiphase MRI has been proposed as a discriminating feature between ChRCC and oncocytoma, though sensitivity is limited (reported in only a small percentage of cases in some series).

Frequency Among Affected Individuals

Because ChRCC is itself the "disease" rather than a phenotype-bearing syndrome, formal HPO frequency annotation of individual signs (e.g., "flank pain in X% of ChRCC patients") is less standardized than for Mendelian disease; most series report the majority of cases as incidentally discovered, with symptomatic presentation (pain, hematuria, mass) more typical of larger or locally advanced tumors.

Quality of Life Impact

Localized, surgically resected ChRCC generally carries minimal long-term QoL impact beyond standard post-nephrectomy renal function considerations. Metastatic disease carries QoL burdens similar to other advanced RCCs, including treatment-related toxicity from targeted/immunotherapy agents (fatigue, hand-foot syndrome with TKIs, immune-related adverse events with checkpoint inhibitors such as colitis and interstitial nephritis) (academic.oup.com/oncolo/29/5/392).

4. Genetic/Molecular Information

Causal/Driver Genes

No single gene is causally sufficient for sporadic ChRCC in the way, e.g., VHL is for clear cell RCC. Instead, ChRCC is defined by a characteristic multi-chromosome loss signature plus a low but recurrent point-mutation burden in TP53 and PTEN (PMID:25155756).

Chromosomal Abnormalities — the defining molecular signature

A hallmark, near-pathognomonic feature: combined monosomy/loss of chromosomes 1, 2, 6, 10, 13, 17, and 21, occurring in 70–93% of cases, first described by comparative genomic hybridization (PMID:7519827) and confirmed by TCGA (loss of most/all of chromosomes 1, 2, 6, 10, 13, and 17 in 86% of cases) (PMID:25155756). Karyotypically, tumors frequently show a markedly hypodiploid chromosome count (32–39), sometimes with subsequent endoreduplication producing a near-diploid or hyperdiploid appearance. This combination of losses is used diagnostically to distinguish ChRCC from renal oncocytoma and other mimics, and the classic morphologic variant loses significantly more chromosomes than the eosinophilic variant (PMID:33021507).

Pathogenic Variants

TP53 (HGNC:11998; chr17p13.1) — ~32% of TCGA cases; missense and truncating mutations; somatic. Associated with worse outcome and enrichment in high-grade/eosinophilic tumors.
PTEN (HGNC:9588; chr10q23.31) — ~9% of cases; somatic loss-of-function; converges with germline PTEN (Cowden syndrome) and FLCN (BHD) pathways on mTORC1 hyperactivation as a recurring pathogenic mechanism.
MTOR, NRAS, TSC1, TSC2 — collectively mutated in ~23% of cases (PMID:25155756), reinforcing mTOR pathway centrality; a Modern Pathology molecular study found mTOR pathway alterations enriched in patients with poor outcome (S0893395222004264).
TERT promoter structural rearrangements — recurrent enhancer-hijacking breakpoints near the TERT promoter, correlating with elevated TERT expression and a localized hypermutation ("kataegis") signature — a distinctive telomerase-reactivation mechanism (PMID:25155756).
FLCN (HGNC:27310; chr17p11.2) — germline biallelic loss in BHD-associated tumors (not typically somatically mutated in sporadic ChRCC).
Mitochondrial DNA (mtDNA) mutations — somatic mtDNA mutations, particularly in genes encoding NADH dehydrogenase (Complex I) subunits, have been reported in ChRCC since early sequencing studies (PMID:12353267). A specific C3572ins insertion in MT-ND1 has been reported in the eosinophilic variant, potentially disrupting Complex I structure/function; ND1 mutations are associated with worse 5-year recurrence-free survival in localized RCC generally (PMID:5187849/PMC5187849). TCGA analysis found ChRCC shows the highest expression of 13 mtDNA-encoded genes among RCC subtypes and increased mitochondrial genome content, with near-universal upregulation of Krebs cycle and electron transport chain (ETC) genes relative to normal kidney (PMID:25155756).

Variant Classification / Allele Frequency

As a somatic cancer-driver context, variants are typically classified via COSMIC/cancer-specific frameworks (pathogenic somatic driver vs. passenger) rather than ACMG/AMP germline classification, except for the germline FLCN, PTEN, TSC1/2, and SDHx variants relevant to hereditary predisposition, which follow standard ClinVar/ACMG classification.

Somatic vs. Germline Origin

The overwhelming majority of ChRCC-associated variants (TP53, PTEN, MTOR pathway, TERT rearrangements, mtDNA mutations, chromosomal losses) are somatic. Germline variants (FLCN in BHD, PTEN in Cowden syndrome) account for the hereditary minority and are associated with characteristic multifocal/bilateral, earlier-onset, hybrid-histology disease.

Functional Consequences

TP53 loss-of-function → impaired p53-dependent transcriptional responses (apoptosis, senescence, DNA damage response).
PTEN loss / MTOR-TSC1/TSC2-NRAS alterations → constitutive mTORC1 pathway activation, driving anabolic growth signaling — the mechanistic rationale for mTOR-inhibitor (everolimus) sensitivity in metastatic disease.
TERT promoter rearrangement → gain-of-function-like transcriptional upregulation of telomerase, promoting replicative immortality.
Complex I mtDNA mutations → altered oxidative phosphorylation efficiency and mitochondrial oxidative stress, proposed as a partially independent (from mTOR) oncogenic axis specific to this tumor's distal-nephron, mitochondria-rich cell of origin (S1040842825003737; PMID:25155756).

Modifier Genes

CDKN1A (p21) loss of mRNA/protein expression has been identified as an independent predictor of poor outcome in ChRCC (PMC7072616), suggesting a modifying role for cell-cycle checkpoint regulators beyond the core driver genes.

Epigenetic Information

TCGA multi-platform analysis included DNA methylation profiling of ChRCC as part of its integrated molecular characterization; ChRCC shows a distinctive expression/methylation profile relative to other RCC subtypes consistent with its distal-nephron/intercalated-cell origin, though disease-specific therapeutic epigenetic targets remain an active research area (S1040842825003737, "emerging vulnerabilities").

Suggested ontology terms: HGNC:11998 (TP53), HGNC:9588 (PTEN), HGNC:27310 (FLCN), HGNC:3942 (TSC1), HGNC:12363 (TSC2), HGNC:3942/HGNC:12395 (MTOR), HGNC:1791 (CDKN1A); GO:0031929 (TOR signaling), GO:0006457 (protein folding — not central here), GO:0006120 (mitochondrial electron transport, NADH to ubiquinone).

5. Environmental Information

Environmental Factors

No disease-specific environmental toxin has been robustly and specifically associated with ChRCC (as distinct from RCC as a whole). General renal carcinogen exposures (trichloroethylene, cadmium, certain herbicides) are studied predominantly in relation to clear cell RCC.

Lifestyle Factors

Smoking and obesity are established general RCC risk factors; ChRCC-specific attributable-risk data are sparse given the tumor's rarity and the difficulty of subtype-stratified epidemiologic studies.

Infectious Agents

Not applicable — ChRCC has no established infectious etiology.

6. Mechanism / Pathophysiology

Causal Chain Overview

ChRCC pathogenesis centers on a convergence of (1) large-scale genomic instability producing the characteristic multi-chromosome loss pattern, (2) recurrent point mutations/pathway alterations converging on mTORC1 hyperactivation (via PTEN, MTOR, TSC1/2, NRAS, or germline FLCN loss), and (3) mitochondrial dysfunction with altered oxidative phosphorylation, reflecting the tumor's origin from mitochondria-rich distal nephron intercalated cells.

Upstream events: - Whole-chromosome losses (1, 2, 6, 10, 13, 17, 21) — an early, near-universal genomic event of unclear precise mechanism, possibly reflecting a distinct chromosomal instability process in the cell of origin. - TERT promoter structural rearrangement — enables replicative immortality.

Midstream/convergent pathway alterations: - PTEN loss / TSC1-TSC2-MTOR-NRAS mutations / germline FLCN loss → loss of negative regulation of mTORC1 → increased protein synthesis, cell growth, and proliferation (GO:0031929, TOR signaling; GO:0038202, TORC1 signaling). - TP53 mutation → impaired DNA damage response/apoptosis, permitting accumulation of further genomic instability; enriched in higher-grade, more aggressive tumors.

Downstream/metabolic consequences: - Increased mitochondrial genome content and near-universal transcriptional upregulation of Krebs cycle and electron transport chain (ETC) genes relative to normal kidney — a metabolic reprogramming distinct from the glycolytic (Warburg) shift typical of clear cell RCC, consistent with ChRCC retaining an oxidative-phosphorylation-dependent metabolic phenotype (PMID:25155756). - Somatic mtDNA mutations (notably in Complex I/ND subunits) may further perturb ETC function and increase oxidative stress, potentially contributing to genomic instability and influencing prognosis (recurrence-free survival) (PMID:5187849).

Cellular Processes

Cell cycle dysregulation (via TP53/CDKN1A axis)
Anabolic growth signaling (mTORC1 pathway) — GO:0016239 not directly, but GO:0045821 (positive regulation of glycolytic process) is more relevant to ccRCC; for ChRCC the relevant term is oxidative-phosphorylation maintenance, GO:0006119 (oxidative phosphorylation).
Impaired apoptosis/DNA damage response (TP53-dependent) — GO:0006977 (DNA damage response, signal transduction by p53).
Telomere maintenance (TERT reactivation) — GO:0007004 (telomere maintenance via telomerase).

Protein Dysfunction

p53: loss of transcriptional activator function (many mutations are missense, disrupting DNA-binding domain function, consistent with dominant-negative or loss-of-function effects typical of TP53 cancer mutations).
PTEN: loss of lipid phosphatase activity (PIP3 → PIP2 dephosphorylation), removing the brake on PI3K-AKT-mTOR signaling.
Mitochondrial Complex I subunits (e.g., ND1): structural/functional impairment from mtDNA insertions/mutations, potentially reducing ETC efficiency.

Metabolic Changes

Distinctive oxidative, mitochondria-centered metabolic phenotype (elevated ETC and Krebs cycle gene expression, increased mtDNA copy number), contrasting with the glycolytic/pseudohypoxic phenotype of VHL-mutant clear cell RCC — an important conceptual distinction, since it implies ChRCC tumor cells may remain relatively dependent on oxidative phosphorylation, a potential therapeutic vulnerability under active investigation (S1040842825003737).

Tissue Damage / Cell of Origin

Immunohistochemical, ultrastructural, and TCGA transcriptomic evidence supports origin from intercalated cells of the distal nephron/cortical collecting duct, distinguishing ChRCC from clear cell RCC (proximal tubule origin) and explaining shared antigenic overlap with the benign oncocytoma (also thought to arise from intercalated cells), which underlies their diagnostic overlap.

Molecular Profiling Summary (TCGA KICH, n=66) (PMID:25155756)

Transcriptomics: Distal-nephron gene expression signature; upregulation of mitochondrial/OXPHOS genes.
Genomics: Low somatic mutation rate overall; dominant signal is arm/whole-chromosome copy-number loss rather than point mutation burden.
mtDNA sequencing: Recurrent somatic mtDNA mutations, particularly Complex I genes.
Structural variation: TERT promoter rearrangements as a recurrent, disease-defining structural event.

Single-Cell / Spatial / Multi-omics

Dedicated single-cell and spatial transcriptomic atlases of ChRCC are less mature than for clear cell RCC given rarity, but emerging work (e.g., studies of the hybrid oncocytic/chromophobe tumor in BHD syndrome) uses sequencing to resolve dual lineage markers capturing the two cellular populations of HOT, distinguishing oncocytoma-like and chromophobe-like cell populations within hybrid tumors (PMC10871670).

7. Anatomical Structures Affected

Organ Level

Primary organ: Kidney (UBERON:0002113), specifically arising in the renal cortex from the distal nephron/collecting duct system.
Secondary/metastatic sites (in advanced disease): lung, liver, bone, and regional lymph nodes — a pattern broadly similar to other RCC subtypes, though metastatic ChRCC is less common than in clear cell RCC given its generally indolent behavior.
Body systems: Genitourinary system primarily; renal insufficiency can occur post-nephrectomy or with bilateral disease (as in BHD syndrome).

Tissue and Cell Level

Tissue type: Renal epithelial (glandular) tissue.
Cell of origin / cell type involved: Intercalated cells of the distal nephron/cortical collecting duct — Cell Ontology candidate term CL:1000497 (kidney collecting duct intercalated cell) or more specifically CL:0002201 (collecting duct intercalated cell).
Tumor cells themselves: large, polygonal cells with abundant pale reticulated cytoplasm ("plant-cell" appearance) and prominent cell membranes.

Subcellular Level

Mitochondria (GO:0005739, mitochondrion) — central to pathophysiology; tumor cells are characteristically packed with mitochondria (contributing to the "chromophobe" — pale, poorly staining — cytoplasmic appearance on light microscopy, related to microvesicle accumulation rather than mitochondrial density per se, though mitochondrial content is elevated at the molecular level per TCGA data).
Cytoplasmic microvesicles (ultrastructurally distinctive, contributing to the finely reticulated cytoplasmic texture).
Nucleus — irregular, wrinkled ("raisinoid") nuclear contour, a key diagnostic feature.

Localization

Renal mass, typically unifocal in sporadic disease; UBERON:0002113 (kidney), more specifically involving the renal parenchyma/cortex.
Lateralization: Usually unilateral in sporadic disease; bilaterality (~3% sporadic) is a hallmark clue to BHD syndrome when present, and multifocality within one kidney occurs in ~8% (PMID:18813125).

8. Temporal Development

Onset

Adult-onset malignancy; mean age at diagnosis ~59 years (range 27–82) (PMID:18813125); some sources note diagnoses clustering in the 40–50 age range as well, reflecting heterogeneity across cohorts, with overall a somewhat younger mean age than clear cell RCC.
Onset pattern: Typically insidious — an asymptomatic mass discovered incidentally on imaging performed for unrelated reasons, reflecting the generally indolent natural history.

Progression

Disease stages: Staged using the standard AJCC/TNM system for renal cell carcinoma (pT1–pT4, N, M), the same staging framework applied across RCC histologic subtypes; ChRCC-specific prognostic nomograms (Leibovich 2018, GRANT models) have also been developed and externally validated using SEER data (PMC10093654).
Progression rate: Generally slow/indolent for classic ChRCC; more rapid and aggressive when sarcomatoid/rhabdoid dedifferentiation, high nuclear grade, or the eosinophilic variant is present.
Disease course pattern: Typically stable/slowly progressive if untreated over years in localized disease; can recur or metastasize years after nephrectomy in a minority of cases, warranting long-term surveillance.
Duration: Curable with surgery in the majority of localized cases; chronic/incurable in the metastatic setting, though median survival even then is measured in years for many patients given the generally favorable underlying biology, in contrast to more rapidly fatal metastatic clear cell RCC.

Patterns

Remission: Surgical resection (partial or radical nephrectomy) is curative in the vast majority of localized cases; no established spontaneous remission pattern.
Critical periods: Early detection via incidental imaging is the primary driver of favorable outcomes; delayed diagnosis with larger tumor size or dedifferentiated (sarcomatoid) transformation is associated with worse prognosis, making surveillance imaging in known predisposition syndromes (e.g., BHD) clinically important for early intervention.

9. Inheritance and Population

Epidemiology

Prevalence/proportion of RCC: ChRCC accounts for approximately 5–7% (range cited 5–10%) of all renal cell carcinomas.
Incidence: Estimated annual age-standardized incidence in Western populations of roughly 0.5–1 per 100,000 individuals.

Inheritance Pattern (for hereditary forms)

Birt–Hogg–Dubé syndrome: Autosomal dominant (FLCN, OMIM #135150); high but incomplete penetrance for cutaneous and pulmonary manifestations, with variable renal tumor risk (lifetime renal tumor risk estimated around 15–30% in various cohorts, though estimates vary).
Cowden syndrome (PTEN hamartoma tumor syndrome): Autosomal dominant (PTEN, OMIM #158350); variable expressivity across the classic Cowden phenotypic spectrum, with RCC (including ChRCC) as one of several associated malignancies alongside breast, thyroid, and endometrial cancer.
Sporadic ChRCC itself, being a somatically driven malignancy, has no Mendelian inheritance pattern.

Penetrance / Expressivity

BHD-associated renal tumor risk is age-dependent and incompletely penetrant; expressivity is variable even within families (histology mix of ChRCC, HOCT, oncocytoma, clear cell, and papillary tumors can differ between affected relatives).

Founder Effects / Consanguinity

Not specifically documented for ChRCC or its associated syndromes; FLCN and PTEN pathogenic variants occur across diverse populations without a strong reported founder-population enrichment specific to renal manifestations.

Population Demographics

Sex ratio: Reported as roughly male:female 1.1:1 in the largest histomorphologic series (PMID:18813125), though other summary sources describe a slight female predominance — the literature is not fully concordant, and sex distribution appears closer to balanced than the male predominance seen in clear cell RCC.
Geographic distribution: No strong endemic geographic clustering reported; distribution roughly parallels general RCC incidence patterns globally, modulated by imaging utilization rates (higher incidental detection in high-resource settings with frequent cross-sectional imaging).
Age distribution: Peak diagnosis in the 5th–6th decade of life; can occur across a wide age range (documented from late 20s to 80s) (PMID:18813125).

10. Diagnostics

Clinical/Laboratory Tests

Routine urinalysis (hematuria assessment), basic metabolic panel/renal function testing — nonspecific, used in general renal mass workup rather than ChRCC-specific diagnosis.
No validated blood or urine biomarker is specific for ChRCC at present.

Imaging Studies

Contrast-enhanced CT — first-line for renal mass characterization; ChRCC typically appears as a well-circumscribed, homogeneously enhancing (often less avidly than clear cell RCC) solid mass, sometimes with a central stellate scar and "spoke-wheel" enhancement pattern (PMID:15479284).
MRI — used particularly to assess segmental enhancement inversion, a proposed (though imperfectly sensitive) discriminator from oncocytoma (PMC11992432).
Multiphase MDCT enhancement pattern analysis has been studied to differentiate ChRCC from other renal masses (AJR.13.10813).

Biopsy / Pathology (definitive diagnosis)

Renal mass core-needle biopsy or nephrectomy specimen — gold standard for diagnosis.
Histopathology: Large polygonal cells with pale, finely reticulated ("wispy") cytoplasm, sharp/distinct ("plant-cell-like") cell membranes, perinuclear halos, and irregular ("raisinoid") nuclear contours; classic vs. eosinophilic morphologic variants recognized.
Special stains: Hale's colloidal iron stain classically shows diffuse cytoplasmic staining in ChRCC (though now used less due to variable/focal staining and superseded largely by immunohistochemistry) (pathologyoutlines.com).
Immunohistochemistry — the "three 7" panel: CK7 (positive, diffusely in >75% of cases), CD117/KIT (positive in ~95.5% of cases), and Claudin-7 — combined use is highly effective for confirming ChRCC and excluding mimics such as oncocytoma (typically CK7-focal/negative) and clear cell RCC (typically CD117-negative) (PMC6815563).
Electron microscopy: Characteristic numerous cytoplasmic microvesicles, historically used to confirm diagnosis in ambiguous cases (PMC4687210).

Genetic Testing

Not routinely required for sporadic ChRCC diagnosis (which is a histopathologic/immunohistochemical diagnosis), but germline FLCN testing should be considered in patients with bilateral/multifocal tumors, hybrid oncocytic/chromophobe histology, young age at diagnosis, or a personal/family history suggestive of BHD syndrome (fibrofolliculomas, spontaneous pneumothorax). Germline PTEN testing is indicated when Cowden syndrome features are present.
Cytogenetic/FISH or copy-number array testing for the characteristic multi-chromosome loss pattern (chromosomes 1, 2, 6, 10, 13, 17, 21) can support diagnosis in histologically ambiguous cases, distinguishing ChRCC from oncocytoma and other mimics.

Differential Diagnosis

Renal oncocytoma — the principal benign mimic; distinguished by more diffuse/uniform CK7-negative or focal staining, absence of the characteristic chromosomal loss pattern, and different nuclear features (though "hybrid oncocytic/chromophobe tumor" represents genuine morphologic overlap, especially in BHD syndrome).
Eosinophilic solid and cystic RCC (ESC-RCC) — a distinct WHO 2022-recognized entity, sometimes TSC1/TSC2-mutated, in the differential for oncocytic renal tumors.
Low-grade oncocytic tumor (LOT) — an emerging provisional entity in the WHO 2022 classification, overlapping morphologically with both oncocytoma and eosinophilic ChRCC.
Succinate dehydrogenase (SDH)-deficient RCC and clear cell RCC (eosinophilic variants) — distinguished by SDHB immunohistochemistry loss and CA-IX/CD10 positivity respectively.

Screening

No population-level screening program exists for sporadic ChRCC given its rarity and generally favorable prognosis. In confirmed BHD syndrome, periodic renal imaging surveillance (e.g., MRI every 1–3 years starting in early adulthood) is recommended given the risk of multiple, recurrent renal tumors.

11. Outcome/Prognosis

Survival and Mortality

ChRCC has a notably favorable prognosis relative to other RCC subtypes: - 5-year overall survival: Reported around 91% in aggregate literature, with SEER-based analyses showing 5-year overall survival for localized, post-nephrectomy disease exceeding 95%, and cancer-specific survival approaching 98%. - 5-year and 10-year cancer-specific survival (broader literature range): 78–100% and 80–90% respectively, reflecting biological behavior of "low malignant potential" for the majority of tumors. - Metastatic disease: Median overall survival is more guarded, approximately 24 months in the targeted-therapy era, underscoring the divergent prognosis between localized and advanced disease.

Prognostic Models

The Leibovich 2018 and GRANT (Grade, Age, Nodes, Tumor) models have been externally validated specifically for non-metastatic ChRCC using a SEER cohort of 5,522 patients, showing moderate discriminative accuracy (concordance ~0.64–0.65 at 10 years) — indicating room for improvement in ChRCC-specific prognostic tools relative to their performance in clear cell RCC (PMC10093654). SEER-based nomograms for overall and cancer-specific survival have also been developed (PMC9438212).

Morbidity and Function

Post-nephrectomy renal function considerations are relevant, particularly with bilateral/multifocal disease (as in BHD syndrome) where nephron-sparing (partial nephrectomy) approaches are prioritized to preserve function across repeated interventions.

Disease Course / Complications

Sarcomatoid and/or rhabdoid dedifferentiation is the principal adverse prognostic feature, associated with markedly worse survival and a shift toward more aggressive, systemic-therapy-requiring disease.
Loss of CDKN1A (p21) mRNA/protein expression is an independent predictor of poor outcome (PMC7072616).
TP53 mutation and mTOR pathway alterations are associated with poorer outcomes in molecular characterization studies (S0893395222004264).
MT-ND1 (mitochondrial Complex I) mutation status has been associated with worse recurrence-free survival in localized RCC (PMC5187849).

Prognostic Factors/Biomarkers

Tumor stage (pT), nuclear grade, presence of sarcomatoid/rhabdoid features, TP53 mutation status, mTOR pathway alteration status, and CDKN1A expression loss are the principal reported prognostic correlates.

12. Treatment

Surgical (primary curative modality)

Partial nephrectomy (nephron-sparing surgery) — preferred when technically feasible, especially important in bilateral/multifocal disease (e.g., BHD syndrome) to preserve renal function across potential repeat surgeries.
Radical nephrectomy — for larger or anatomically unfavorable tumors.
NCIT suggested term: NCIT:C15329 (Surgical Procedure); more specifically partial/radical nephrectomy procedure codes.

Pharmacotherapy — Metastatic/Advanced Disease

mTOR inhibitors (everolimus) — mechanistically well-supported given the mTORC1 pathway centrality in ChRCC pathogenesis (via PTEN/TSC1/TSC2/MTOR mutations and FLCN loss in hereditary cases); the ASPEN phase II study reported a chromophobe RCC cohort progression-free survival of 11.4 months with everolimus, among the better-performing non-clear-cell RCC histologies in that trial.
NCIT: NCIT:C15986 (Pharmacotherapy); therapeutic_agent CHEBI term for everolimus (CHEBI:68478).
VEGFR tyrosine kinase inhibitors (sunitinib, cabozantinib, pazopanib) — used per general non-clear-cell RCC guidelines; case reports document exceptional responses of metastatic ChRCC to VEGF inhibitors, with increased VEGF-C expression proposed as a potential predictive biomarker in some cases (PMC6949673).
Combination regimens — current NCCN-guideline-informed approaches for advanced non-clear-cell RCC (including ChRCC) favor doublet therapy: VEGFR-inhibitor + mTOR-inhibitor, VEGFR-inhibitor + immune checkpoint inhibitor, or doublet checkpoint inhibition, extrapolated substantially from broader RCC trials given the paucity of ChRCC-specific randomized data.
Lenvatinib plus everolimus — evaluated in a phase 2 study for advanced non-clear-cell RCC including ChRCC (PMC12684810).
Pembrolizumab plus lenvatinib — under investigation in the first-line advanced/metastatic non-clear-cell RCC setting (KEYNOTE trial program, NCT04704219).

Immunotherapy

Immune checkpoint inhibitors (nivolumab, ipilimumab-nivolumab combination) — case reports document significant responses in metastatic ChRCC with sarcomatoid differentiation, including a notable case of response to nivolumab as seventh-line therapy (PMID:29558933/PMC5907256) and additional cases using combination checkpoint blockade as first-line therapy for sarcomatoid ChRCC (link.springer.com/10.1007/s13691-022-00561-y). Immune-related adverse events reported include interstitial nephritis and colitis.
NCIT term candidates: monoclonal antibody / immune checkpoint inhibitor class terms; therapeutic_modality: MONOCLONAL_ANTIBODY.

Treatment for Sarcomatoid/Rhabdoid Dedifferentiation

This aggressive subset is treated more like sarcomatoid RCC generally: combination immune checkpoint therapy is a preferred first-line approach; cabozantinib as second/third-line therapy after progression on VEGFR-TKI or checkpoint inhibitor combinations has shown objective response rates of 44–47% in retrospective multicenter series of sarcomatoid-dedifferentiated RCC (academic.oup.com/oncolo/29/5/392).

Surveillance/Active Monitoring

Active surveillance is a reasonable option for small, incidentally discovered renal masses in appropriately selected (e.g., elderly, comorbid) patients, given ChRCC's generally indolent behavior, though tissue diagnosis (biopsy) is typically pursued first given the differential with oncocytoma and other entities.

Experimental/Emerging

Given ChRCC's distinctive mitochondrial/oxidative phosphorylation-dependent metabolism, targeting mitochondrial vulnerabilities has been proposed as an emerging therapeutic strategy, reviewed as "emerging vulnerabilities" for a new therapeutic landscape in recent literature (S1040842825003737). HIF2α inhibitors (e.g., belzutifan) are primarily developed for VHL-pathway-driven clear cell RCC and are not a standard mechanistic fit for ChRCC, though broader RCC trials sometimes include mixed histology cohorts.

13. Prevention

Primary Prevention

No specific primary prevention strategy exists for sporadic ChRCC beyond general cancer risk-factor modification (smoking cessation, weight management) applicable to RCC broadly.

Secondary Prevention / Screening

In confirmed hereditary predisposition (BHD syndrome, Cowden syndrome), periodic renal imaging surveillance (typically MRI to limit cumulative radiation exposure given repeated lifetime studies) is recommended to enable early detection and nephron-sparing surgical management before tumors grow large or multiply.
Incidental detection via imaging performed for unrelated indications remains the dominant "screening" mechanism for sporadic disease in practice, given the absence of a formal population screening program.

Genetic Counseling

Recommended for patients with bilateral/multifocal renal tumors, hybrid oncocytic/chromophobe histology, or a personal/family history suggestive of BHD syndrome (fibrofolliculomas, spontaneous pneumothorax history) or Cowden syndrome, to guide germline testing (FLCN, PTEN) and cascade testing of at-risk relatives.

Prophylaxis

Not applicable in the pharmacologic sense; nephron-sparing surgical strategy in known predisposition syndromes functions as a form of tertiary/preventive management to preserve long-term renal function against anticipated recurrent tumor development.

14. Other Species / Natural Disease

Taxonomy

Primarily a human disease entity (NCBITaxon:9606); renal epithelial tumors morphologically and molecularly analogous to ChRCC are not well established as a naturally occurring veterinary disease entity in the way, e.g., some hereditary cancer syndromes are documented in dogs.

Comparative/Model Relevance

Comparative biology work has focused on genetically engineered mouse models rather than naturally occurring animal disease (see Model Organisms below). No substantial OMIA (Online Mendelian Inheritance in Animals) entry specific to ChRCC-equivalent naturally occurring disease was identified in this research pass.

Transmission

Not applicable — ChRCC is a non-communicable, non-zoonotic malignancy.

15. Model Organisms

Genetically Engineered Mouse Models

Kidney-specific Flcn knockout mouse — proximal-tubule-targeted disruption of Flcn produces renal cysts and early-onset (~6 months), high-penetrance multi-histology renal neoplasia; the majority of tumors in affected mice under 1 year of age are chromophobe RCC-like, with papillary RCC predominating in older knockout mice. Both mTOR and TGF-β signaling pathways are upregulated in Flcn-deficient tumors, directly modeling the human BHD-associated tumor biology, and treatment with the mTOR inhibitor rapamycin for 10 months suppressed tumor growth in this model — providing preclinical rationale for mTOR-inhibitor use in human BHD-associated and sporadic ChRCC (sciencedirect.com/S0085253815609875).

Cell Line Models

UOK276 — a spontaneously immortalized human cell line derived from a large chromophobe RCC with regions of sarcomatoid differentiation; hyperdiploid with a modal chromosome number of 49 and evidence of copy-neutral loss of heterozygosity. Genomic and metabolic characterization of UOK276 supports its use as a model for studying aggressive, sarcomatoid-differentiated ChRCC and associated treatment resistance (PMC5561006).

Model Characteristics — Phenotype Recapitulation and Limitations

The Flcn-knockout mouse recapitulates the mTOR/TGF-β pathway activation and histologic spectrum (including a ChRCC-predominant early phenotype transitioning to papillary-predominant with age) seen in human BHD-associated renal tumors, and demonstrates in vivo therapeutic responsiveness to rapamycin — a translationally validated model. A limitation is that this model specifically captures the FLCN-driven hereditary pathway rather than the chromosome-loss/TP53/mtDNA-driven sporadic ChRCC pathway, which currently lacks an equally well-validated genetically engineered mouse model reproducing the characteristic multi-chromosome-loss genomic signature.

Applications

These models support mechanistic study of mTOR pathway dependency (rationale for everolimus use), sarcomatoid dedifferentiation biology and drug resistance (UOK276), and preclinical testing of mitochondrial-pathway-targeted therapeutics given ChRCC's distinctive oxidative metabolic phenotype.

Resources

Mouse Genome Informatics (MGI) for Flcn allele records; Cellosaurus/ATCC for UOK276 and related renal cancer cell line characterization data.

Summary of Suggested Ontology Term Bindings for KB Curation

Table (click to expand)

Category	Term
Disease	MONDO:0017885 (chromophobe renal cell carcinoma)
Disease (hereditary)	MONDO for Birt-Hogg-Dube syndrome; OMIM #135150
Causal genes	HGNC:11998 (TP53), HGNC:9588 (PTEN), HGNC:27310 (FLCN), HGNC:3942/12395 (TSC1/TSC2 relevant IDs), MTOR
Cell type	CL term for kidney collecting duct intercalated cell (e.g., CL:1000497/CL:0002201)
Anatomy	UBERON:0002113 (kidney)
Biological process	GO:0031929/GO:0038202 (TOR/TORC1 signaling), GO:0006119 (oxidative phosphorylation), GO:0006977 (DNA damage response via p53), GO:0007004 (telomere maintenance via telomerase)
Phenotypes	HP:0000790 (Hematuria), HP:0030057 (Flank pain), HP:0031817 (Abdominal mass)
Treatment	NCIT:C15329 (Surgical Procedure), NCIT:C15986 (Pharmacotherapy) with therapeutic_agent CHEBI:68478 (everolimus)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	30
Resolved	30
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.